Derbyshire Medicines Management and Clinical Policies
Home
Medicines Management
Full Traffic Light Classification
Show Drug
Repaglinide
Size guide:
A
A
A
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Deprescribing
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Inappropriate Requests and Prescribing Concerns in Primary Care
Print this page
Add shortcut to your smart phone
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Deprescribing
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Repaglinide
Search the site
Search
BNF:
6.1.2.3
Status:
Grey
Decision Date:
July 2016
Comments
Recommended by local diabetologists; limited for use in early diabetes or for patients with an erratic lifestyle.
Grey Drug Classifications
6: NICE guidance
search again
Derby and Derbyshire ICB